At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 356 enrolled
Drug / intervention
Abataceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ib, Multicenter, Randomized, Open-Label, Parallel-Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject™ Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe
In Brief
A Phase 1 clinical trial evaluating Abatacept for Rheumatoid Arthritis. Completed, enrolled 356 participants across 25 sites in 5 countries.
Detailed Summary
The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Mexico, Peru, South Africa, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartJul 2013
Primary CompletionNov 2014
TodayJul 2026
First PostedJul 1, 2013
Enrollment StartJul 1, 2013
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.0 years ago
Interventions
Abataceptdrug